Neurontin Patent Defense Takes Center Stage In Senate Hearing
Executive Summary
Pfizer's anti-epileptic drug Neurontin is claiming the spotlight as the most frequently cited "abuse" of the Hatch/Waxman patent defense process
You may also be interested in...
Paxil Late-Listed Patents Are Questionable For Orange Book Listing – FTC
Generic versions of Paxil are being held up by patents whose listing in the "Orange Book" is questionable, the Federal Trade Commission's generic drug report states
Paxil Late-Listed Patents Are Questionable For Orange Book Listing – FTC
Generic versions of Paxil are being held up by patents whose listing in the "Orange Book" is questionable, the Federal Trade Commission's generic drug report states
Patent Disputes Do Not Pay Off, Merck Says: Sweet Spot In “Bitter Medicine”
Aggressive patent defensive strategies do not pay off on Wall Street, Merck CEO Ray Gilmartin told Peter Jennings during an ABC News special, "Bitter Medicine: Pills, Profit and the Public Health," which aired May 29